EGFR and small cell lung carcinoma: Osimertinib resistance can be broadly grouped into EGFR-dependent mechanisms, such as C797X mutations, and EGFR-independent mechanisms, such as the amplification of MET and HER2, epithelial-mesenchymal transition (EMT) and small cell lung cancer transformation [5–7].